Maria Francesca Sarnelli

TL;DR: A safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials, while warranting good reproducibility is described.

TL;DR: The data support the hypothesis that ALS pathology disseminates in a regional ordered sequence, through a cortico-efferent spreading model, and suggest that ALS motor and cognitive components may worsen in parallel, and that cognitive impairment becomes more pronounced when bulbar function is involved.

TL;DR: The data suggest that the spatial–temporal combination of motor and cognitive events leading to the onset and progression of ALS is characterized by a differential susceptibility to the pathologic process of motorand prefrontal cortices and lower motor neurons, and is influenced by age, sex, and gene variants.

TL;DR: The results show that transplantation of hNSC is a safe procedure that causes no major deleterious effects over the short or long term, and the observations support undertaking future phase II clinical studies in which increased cell dosages are studied in larger cohorts of patients.

TL;DR: It is found that those who changed their cognitive status presented a lower ALSFRS-r score at t1 and a shorter survival time compared to those who did not change, regardless of the type of cognitive impairment.